Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	BIO-TECHNE CORPORATION

Date: August 23, 2023		/s/ Charles R. Kummeth
			By:	Charles R. Kummeth
			Its:	President and CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


Date		Signature and Title

August 23, 2023		/s/ Robert V. Baumgartner
		Robert V. Baumgartner
		Chairman of the Board and Director

August 23, 2023		/s/ Julie Bushman
		Julie Bushman, Director

August 23, 2023		/s/ Rupert Vessey
		Dr. Rupert Vessey, Director

August 23, 2023		/s/ Joseph Keegan, Ph.D.
		Dr. Joseph Keegan, Director

August 23, 2023		/s/ John L. Higgins
		John L. Higgins, Director

August 23, 2023		/s/ Roeland Nusse, Ph.D.
		Dr. Roeland Nusse, Director

August 23, 2023		/s/ Alpna Seth, Ph.D.
		Dr. Alpna Seth, Director

August 23, 2023		/s/ Randolph C. Steer, Ph.D., M.D.
		Dr. Randolph C. Steer, Director

August 23, 2023		/s/ Charles R. Kummeth
		Charles R. Kummeth, Director and Chief Executive Officer (principal executive officer)

August 23, 2023		/s/ James Hippel
		James Hippel, Chief Financial Officer
		(principal financial officer and principal accounting officer)

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES